Rabbit anti grp78

The following antibodies were used in this study: rabbit anti-GRP78 and rabbit anti-ERp29 from Novus Biologicals (Littleton, CO); rabbit anti-eIF2a, mouse anti-phospho-eIF2a (S51), rabbit anti-p58^IPK, rabbit anti-cleaved PARP, rabbit anti-spliced XBP-1 (XBP-1s), rabbit anti-cleaved caspase 3and mouse anti-GADD153/CHOP from Cell Signalling Technology (Beverly, MA); mouse anti-β-actin from Sigma-Aldrich (St Louis, MO); rabbit anti-CaMKII, rabbit anti-Bax, rabbit anti-caspase 12 and rabbit anti-phospho-CaMKII (T286) from Abcam (Cambridge, MA).
Fucoidan isolated from Fucus vesiculosus was purchased from Sigma-Aldrich (Saint Louis, MO). The complete, EDTA-free protease inhibitor cocktail tablets were obtained from Roche Diagnostics (Indianapolis, IN). Phosphatase cocktail inhibitors I and II and thapsigargin (TG) were from Sigma-Aldrich (Steinheim, Germany). Lipofectamine 2000 transfection reagents were supplied from Invitrogen (Eugene, OR). Salubrinal was purchased from Tocris Bioscence (Ellisville, MO).

Rabbit anti-GRP78 (also called BiP; 1:4000, Novus Biologicals, San Diego, CA, United States), monoclonal mouse anti-TDP43 (1:32,000, Abcam, San Francisco, CA, United States), guinea pig anti-BMAL1 (1:15,000, Millipore, Billerica, MA, United States), and sheep anti-GFP (1:3,000, AbD Serotec, Raleigh, NC, United States) were used. Species appropriate, fluorophore-conjugated, minimally cross reactive secondary antibodies were obtained from Jackson Immuno (West Grove, PA, United States) and used at a concentration of 1:500. Specificity of anti-BiP antibody was previously verified via siRNA knockdown (Kitahara et al., 2011 (link); Maddalo et al., 2012 (link)). Specificity of anti-TDP43 antibody was previously verified via shRNA knockdown (Lee et al., 2015 (link)). Specificity of anti-Bmal1 antibody was verified in Bmal^−/− tissue (LeSauter et al., 2012 (link)).